Design, Synthesis and<i>In Vitro</i>Study of 5,6-Diaryl-1,2,4-triazine-3-ylthioacetate Derivatives as COX-2 and β-Amyloid Aggregation Inhibitors
作者:Sakineh Dadashpour、Tuba Tuylu Kucukkilinc、Oya Unsal Tan、Keriman Ozadali、Hamid Irannejad、Saeed Emami
DOI:10.1002/ardp.201400400
日期:2015.3
6‐diaryl‐1,2,4‐triazine‐3‐ylthioacetate derivatives were synthesized and their chemical structures were confirmed by NMR, IR and MS spectra. Further in vitro COX‐1/COX‐2 evaluations revealed that compound 6c (COX‐2 IC50 = 10.1 μM, COX‐1 IC50 = 88.8 μM) is the most selective COX‐2 inhibitor while maintaining residual inhibition of COX‐1. In order to evaluate their potential use against AD, an in vitro evaluation
为了寻找新的环氧合酶 (COX)-2 抑制剂来治疗阿尔茨海默病 (AD) 等炎症性疾病,将羧酸乙酯侧链添加到 5-(4-氯苯基)-6-(4-(甲基磺酰基)苯基)-3-(甲硫基)-1,2,4-三嗪(先导化合物 II)通过与 Arg120 相互作用维持对 COX-1 的残留抑制。对 COX-1/COX-2 活性位点的初步分子对接研究确实证实了我们的假设。因此,合成了一系列 5,6-二芳基-1,2,4-三嗪-3-基硫代乙酸乙酯衍生物,并通过 NMR、IR 和 MS 光谱证实了它们的化学结构。进一步的体外 COX-1/COX-2 评估显示化合物 6c(COX-2 IC50 = 10.1 μM,COX-1 IC50 = 88.8 μM)是最具选择性的 COX-2 抑制剂,同时保持对 COX-1 的残留抑制。为了评估它们对 AD 的潜在用途,进行了 β-淀粉样蛋白原纤维形成的体外评估。结果表明,原型化合物